Validation experiment designed to validate causal mechanisms targeting ID in in_silico. Primary outcome: Validate Protein Aggregation Kinetic Validation Results
Description
Protein Aggregation Kinetic Validation Results
Background and Rationale
This validation study aims to experimentally verify computational predictions of protein aggregation kinetics using Thioflavin-T (ThT) fluorescence assays, addressing a critical gap in neurodegeneration research where protein misfolding and aggregation drive pathology. Protein aggregation is a hallmark of neurodegenerative diseases including Alzheimer's, Parkinson's, and Huntington's disease, making accurate prediction of aggregation kinetics essential for therapeutic development. The study leverages multiscale protein aggregation modeling predictions from Experiment ID 15854, which generated theoretical aggregation curves, lag times, and growth rates for various disease-associated proteins under different conditions. The experimental design employs a systematic validation approach using ThT fluorescence, a gold-standard method for detecting amyloid fibril formation in real-time. ThT exhibits enhanced fluorescence upon binding to cross-beta sheet structures characteristic of amyloid fibrils, providing quantitative kinetic data including nucleation lag time, elongation rate, and final fibril yield....
Protein Aggregation Kinetic Validation Results
Background and Rationale
This validation study aims to experimentally verify computational predictions of protein aggregation kinetics using Thioflavin-T (ThT) fluorescence assays, addressing a critical gap in neurodegeneration research where protein misfolding and aggregation drive pathology. Protein aggregation is a hallmark of neurodegenerative diseases including Alzheimer's, Parkinson's, and Huntington's disease, making accurate prediction of aggregation kinetics essential for therapeutic development. The study leverages multiscale protein aggregation modeling predictions from Experiment ID 15854, which generated theoretical aggregation curves, lag times, and growth rates for various disease-associated proteins under different conditions. The experimental design employs a systematic validation approach using ThT fluorescence, a gold-standard method for detecting amyloid fibril formation in real-time. ThT exhibits enhanced fluorescence upon binding to cross-beta sheet structures characteristic of amyloid fibrils, providing quantitative kinetic data including nucleation lag time, elongation rate, and final fibril yield. The study will test multiple protein variants, concentrations, and environmental conditions to establish the predictive accuracy and limitations of the computational models. Key measurements include ThT fluorescence intensity over time, aggregation half-times, maximum aggregation rates, and final plateau values. Innovation lies in the direct quantitative comparison between in silico predictions and experimental data, establishing validation metrics for computational protein aggregation models. This work is significant for advancing predictive capabilities in neurodegeneration research, enabling faster screening of potential therapeutic interventions and providing validated tools for understanding disease mechanisms at the molecular level.
This experiment directly tests predictions arising from the following hypotheses:
Heat Shock Protein 70 Disaggregase Amplification
Stress Granule Phase Separation Modulators
Low Complexity Domain Cross-Linking Inhibition
Cross-Seeding Prevention Strategy
Glycine-Rich Domain Competitive Inhibition
Experimental Protocol
Phase 1: Protein Preparation and Quality Control (Days 1-3) - Express and purify target proteins using established protocols, confirm identity by mass spectrometry, assess purity by SDS-PAGE (>95%), and determine concentration by UV-Vis spectroscopy. Store proteins at -80°C in aggregation-compatible buffers. Phase 2: ThT Assay Optimization (Days 4-5) - Prepare fresh 1mM ThT stock solution, optimize ThT concentration (10-50μM range), validate buffer conditions matching computational model parameters (pH 7.4, ionic strength 150mM), and establish baseline fluorescence measurements. Phase 3: Kinetic Aggregation Assays (Days 6-14) - Load 96-well black plates with 200μL reactions containing protein (1-10μM concentrations), ThT (25μM final), and appropriate buffers. Include negative controls (buffer only, ThT only) and positive controls (pre-formed fibrils). Incubate at 37°C with continuous orbital shaking (300rpm). Monitor ThT fluorescence (Ex: 440nm, Em: 480nm) every 10 minutes for 7 days using plate reader with temperature control. Run each condition in octuplicate (n=8). Phase 4: Data Analysis and Model Comparison (Days 15-17) - Extract kinetic parameters using sigmoidal curve fitting, calculate lag times, growth rates, and maximum fluorescence values. Compare experimental parameters to computational predictions using correlation analysis, calculate prediction accuracy metrics, and perform statistical validation using appropriate tests.
Expected Outcomes
1. Strong positive correlation (R² > 0.8) between computationally predicted and experimentally measured aggregation lag times across different protein concentrations and conditions.
2. Experimental validation of predicted concentration-dependent aggregation kinetics, with 2-fold increase in protein concentration resulting in 50-70% reduction in lag time as predicted by models.
3. Quantitative agreement between predicted and measured maximum aggregation rates within 25% margin of error for at least 80% of tested conditions.
4. Successful recapitulation of predicted pH and ionic strength effects on aggregation kinetics, with experimental data falling within 95% confidence intervals of computational predictions.
5. Identification of model limitations through systematic deviations in specific conditions, particularly at extreme concentrations (<1μM or >20μM) where surface effects may dominate.
6. Establishment of validated aggregation kinetic parameters for at least 5 disease-relevant protein variants, providing benchmark data for future computational model refinement.
Success Criteria
• Achieve >75% accuracy in predicting aggregation lag times within 2-fold of experimental values across all tested conditions
• Demonstrate statistically significant correlation (p < 0.001) between predicted and experimental kinetic parameters with R² > 0.7
• Successfully validate concentration-dependent effects with <30% deviation from predicted trends for at least 4 out of 5 protein concentrations tested
• Obtain reproducible experimental data with coefficient of variation <20% between technical replicates for all kinetic measurements
• Complete kinetic profiling for minimum 3 different proteins under 5 distinct buffer conditions each, generating comprehensive validation dataset
• Establish quantitative metrics for model performance that can be applied to future computational predictions in neurodegeneration research
TARGET GENE
ID
MODEL SYSTEM
in_silico
ESTIMATED COST
$120,000
TIMELINE
7 months
PATHWAY
N/A
SOURCE
wiki
PRIMARY OUTCOME
Validate Protein Aggregation Kinetic Validation Results
Phase 1: Protein Preparation and Quality Control (Days 1-3) - Express and purify target proteins using established protocols, confirm identity by mass spectrometry, assess purity by SDS-PAGE (>95%), and determine concentration by UV-Vis spectroscopy. Store proteins at -80°C in aggregation-compatible buffers. Phase 2: ThT Assay Optimization (Days 4-5) - Prepare fresh 1mM ThT stock solution, optimize ThT concentration (10-50μM range), validate buffer conditions matching computational model parameters (pH 7.4, ionic strength 150mM), and establish baseline fluorescence measurements. Phase 3: Kinetic Aggregation Assays (Days 6-14) - Load 96-well black plates with 200μL reactions containing protein (1-10μM concentrations), ThT (25μM final), and appropriate buffers.
...
Phase 1: Protein Preparation and Quality Control (Days 1-3) - Express and purify target proteins using established protocols, confirm identity by mass spectrometry, assess purity by SDS-PAGE (>95%), and determine concentration by UV-Vis spectroscopy. Store proteins at -80°C in aggregation-compatible buffers. Phase 2: ThT Assay Optimization (Days 4-5) - Prepare fresh 1mM ThT stock solution, optimize ThT concentration (10-50μM range), validate buffer conditions matching computational model parameters (pH 7.4, ionic strength 150mM), and establish baseline fluorescence measurements. Phase 3: Kinetic Aggregation Assays (Days 6-14) - Load 96-well black plates with 200μL reactions containing protein (1-10μM concentrations), ThT (25μM final), and appropriate buffers. Include negative controls (buffer only, ThT only) and positive controls (pre-formed fibrils). Incubate at 37°C with continuous orbital shaking (300rpm). Monitor ThT fluorescence (Ex: 440nm, Em: 480nm) every 10 minutes for 7 days using plate reader with temperature control. Run each condition in octuplicate (n=8). Phase 4: Data Analysis and Model Comparison (Days 15-17) - Extract kinetic parameters using sigmoidal curve fitting, calculate lag times, growth rates, and maximum fluorescence values. Compare experimental parameters to computational predictions using correlation analysis, calculate prediction accuracy metrics, and perform statistical validation using appropriate tests.
Expected Outcomes
1. Strong positive correlation (R² > 0.8) between computationally predicted and experimentally measured aggregation lag times across different protein concentrations and conditions.
2. Experimental validation of predicted concentration-dependent aggregation kinetics, with 2-fold increase in protein concentration resulting in 50-70% reduction in lag time as predicted by models.
3. Quantitative agreement between predicted and measured maximum aggregation rates within 25% margin of error for at least 80% of tested conditions.
4.
...
1. Strong positive correlation (R² > 0.8) between computationally predicted and experimentally measured aggregation lag times across different protein concentrations and conditions.
2. Experimental validation of predicted concentration-dependent aggregation kinetics, with 2-fold increase in protein concentration resulting in 50-70% reduction in lag time as predicted by models.
3. Quantitative agreement between predicted and measured maximum aggregation rates within 25% margin of error for at least 80% of tested conditions.
4. Successful recapitulation of predicted pH and ionic strength effects on aggregation kinetics, with experimental data falling within 95% confidence intervals of computational predictions.
5. Identification of model limitations through systematic deviations in specific conditions, particularly at extreme concentrations (<1μM or >20μM) where surface effects may dominate.
6. Establishment of validated aggregation kinetic parameters for at least 5 disease-relevant protein variants, providing benchmark data for future computational model refinement.
Success Criteria
• Achieve >75% accuracy in predicting aggregation lag times within 2-fold of experimental values across all tested conditions
• Demonstrate statistically significant correlation (p < 0.001) between predicted and experimental kinetic parameters with R² > 0.7
• Successfully validate concentration-dependent effects with <30% deviation from predicted trends for at least 4 out of 5 protein concentrations tested
• Obtain reproducible experimental data with coefficient of variation <20% between technical replicates for all kinetic measurements
• Complete kinetic profiling for minimum 3 diffe
...
• Achieve >75% accuracy in predicting aggregation lag times within 2-fold of experimental values across all tested conditions
• Demonstrate statistically significant correlation (p < 0.001) between predicted and experimental kinetic parameters with R² > 0.7
• Successfully validate concentration-dependent effects with <30% deviation from predicted trends for at least 4 out of 5 protein concentrations tested
• Obtain reproducible experimental data with coefficient of variation <20% between technical replicates for all kinetic measurements
• Complete kinetic profiling for minimum 3 different proteins under 5 distinct buffer conditions each, generating comprehensive validation dataset
• Establish quantitative metrics for model performance that can be applied to future computational predictions in neurodegeneration research